Browsing by Subject "Middle East Respiratory Syndrome (MERS)"
Now showing items 1-10 of 10
-
Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis
(2020-09-18)Background: The new coronavirus-related pneumonia is causing a global pandemic without specific antiviral drug. Ribavirin has activity against extensive RNA and DNA viruses. We plan to systematically review the use of ... -
Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. Interim guidance, 17 March 2020
(2020-03-17)Background: WHO has developed this interim guidance to meet the need for recommendations on safe home care for patients with suspected COVID-19 who present with mild symptomsa and on public health measures related to the ... -
Immune response following infection with SARS‐CoV‐2 and other coronaviruses: A rapid review
(2020-09-23)In this review, we systematically searched and summarized the evidence on the immune response and reinfection rate following SARS‐CoV‐2 infection. We also retrieved studies on SARS‐CoV and MERS‐CoV to assess the long‐term ... -
Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected Interim guidance, 19 March 2020
(2020-03-19)Background: This is the first edition of guidance on infection prevention and control (IPC) strategies for use when COVID-19 is suspected. It has been adapted from WHO’s Infection prevention and control during health care ... -
Infection Prevention and Control guidance for Long-Term Care Facilities in the context of COVID-19, Interim guidance 21 March 2020
(2020-03-21)Background: On 30 January 2020, WHO announced that the COVID-19 outbreak was a Public Health Emergency of International Concern. Initially, most cases were reported from China and among individuals with travel history to ... -
Lopinave/Litonawe (LPV/r) reduced mortality in studies of SARS and MERS: uncertain if it is effective for patients with COVID-19
(2020-03-20)What is this? Like COVID-19, severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) are acute respiratory diseases caused by a coronavirus. Antiviral therapy with Lopinave/Litonawe (LPV/r) ... -
Possible Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Public Bath Center in Huai’an, Jiangsu Province, China
(2020-03-30)Introduction: In December 2019, a novel pneumonia named coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, and has since spread to 25 ... -
Potential interventions for novel coronavirus in China: A systematic review
(2020-02-04)An outbreak of a novel coronavirus (COVID‐19 or 2019‐CoV) infection has posed significant threats to international health and the economy. In the absence of treatment for this virus, there is an urgent need to find alternative ... -
Prevenção e controle de infecção durante os cuidados de saúde quando houver suspeita de infecção pelo novo coronavírus (nCoV)
(2020-01-25)[Introdução]: Esta é a primeira edição de orientações sobre estratégias de prevenção e controle de infecção (PCI) para utilizar quando houver suspeita de infecção por um novo coronavírus (2019-nCoV). Foi adaptado do guia ... -
Ribavirin was beneficial for patients with SARS and MERS: uncertain if it is effective for patients with COVID-19
(2020-03-20)Citation: Luo T, Na Y, Tan L, et al. The Possibility of Ribavirin in the Treatment of the Coronavirus Disease 2019: A Systematic Review. China Pharmaceuticals 2020; 29(5): 34-9 Language: Chinese What is this? Like COVID-19, ...